Claims

We claim:

1. A compound of Formula (I),



(I)

or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, wherein

X is C–R^4;

Y is N–R^5 or O;

R^1 is L^1-R^6, or L^1-R^6-L^2-R^7;

R^2 is H, Hal, OH, OA, CN, NH_2, or NHA;

R^3 is H, CH_3, or $C(Hal)_3$;

R^4 is H, Hal, OH, COOH, NH_2, or CN;

R^5 is H, LA, or monocyclic alkyl having 3, 4, 5, 6, or 7 ring atoms, wherein one or two CH_2 groups themselves may be replaced by a –NH– group, or

L^1, L^2 are each independently a single bond, or unbranched or branched alkyl having 1, 2, 3, 4 or 5 C atoms, in which hydrogen atom of the alkyl may be unsubstituted, or mono- or disubstituted with Hal, OH, NH_2, NH(LA), $N(LA)_2$, and wherein one or two CH_2 groups themselves may be replaced by a –CO–, –NH–, –N(LA)-, –CONH–, –N(LA)COO– or –NHCO– group;

R^6, R^7 are each independently Ar or a monocyclic alkyl having 3, 4, 5, 6, or 7 ring atoms, wherein one or two CH_2 groups themselves may be replaced by an –NH–, –NA-, –CHA-, –CO– or –CONHA- group;

Ar is each independently a mono- or bicyclic aromatic homo- or heterocycle having 0, 1, 2, 3 or 4 N, O and/or S atoms and 5, 6, 8, 9, or 10 skeleton atoms, in which hydrogen atom of the aromatic homo- or heterocycle may be unsubstituted or, independently of one another, mono-, di- or trisubstituted by Hal, A, OA, OH, NH_2, or NHA;

A is each independently an unbranched or branched linear or cyclic alkyl having 1, 2, 3, 4, 5 or 6 C atoms, wherein one or two CH2 groups themselves may be replaced by an O atom and/or an –NH–, –NHCOAr or –CONHAr group wherein 1-3 H atoms may be replaced by Hal, and wherein one or two CH_3 groups may be replaced by NH_2, OH, NH(LA) or $N(LA)_2$ group;
LA is each independently an unbranched or branched, linear alkyl having 1, 2, 3, or 4 C atoms wherein 1, 2 or 3 H atoms may be replaced by Hal; and
Hal is each independently F, Cl, Br or I.

2. The compound according to Claim 1, wherein the compound is selected from:
(S)-5-((1-(3-fluorophenyl)-2-(methylamino)ethyl)amino)quinoline-8-carboxamide;
5-((-4-(quinolin-7-yl)pyrrolidin-3-yl)amino)quinoline-8-carboxamide;
5-((3-phenylazetidin-3-yl)amino)quinoline-8-carboxamide;
5-(((3-(phenylcarbamoyl)pyrrolidin-3-yl)methyl)amino)quinoline-8-carboxamide;
5-((-4-(3-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)amino)quinoline-8-carboxamide;
5-(((4S)-4-(3-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)amino)quinoline-8-carboxamide;
5-(((3S,4R)-4-(3-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)amino)quinoline-8-carboxamide;
5-((-4-(3-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)amino)quinoline-8-carboxamide;
5-((4-(3-fluorophenyl)piperidin-3-yl)amino)quinoline-8-carboxamide;
5-(((4R)-4-(3-chloro-5-fluorophenyl)pyrrolidin-3-yl)amino)quinoline-8-carboxamide;
5-((4S)-4-(3-fluorophenyl)pyrrolidine-3-carboxamido)quinoline-8-carboxamide;
5-((4S)-4-phenylpyrrolidine-2-carboxamido)quinoline-8-carboxamide;
5-(2-amino-2-phenylacetamido)quinoline-8-carboxamide;
5-((3S)-3-phenylazetidine-2-carboxamido)quinoline-8-carboxamide;
5-(4-Fluorobenzylamino)-quinoline-8-carboxamide;
5-(2-Fluorobenzylamino)-quinoline-8-carboxamide;
5-(3-Fluorobenzylamino)-quinoline-8-carboxamide;
5-(3-Chlorobenzylamino)-quinoline-8-carboxamide;
5-(3,4-Difluorobenzylamino)-quinoline-8-carboxamide;
5-(3,4,5-trifluorobenzylamino)-quinoline-8-carboxamide;
5-(4-Fluoro-3-trifluoromethylbenzylamino)-quinoline-8-carboxamide;
5-(4-Chloro-3-trifluoromethylbenzylamino)-quinoline-8-carboxamide;
5-((1-phenyl-2(pyrrolidin-1-yl)ethyl)amino-quinoline-8-carboxamide;
5-(Phenylethylamino)-quinoline-8-carboxamide;

5-(Phenylpropylamino)-quinoline-8-carboxamide; and
5-(Benzylamino)quinoline-8-carboxamide;
or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios.

3. A pharmaceutical composition comprising a compound of Claim 1, and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, as active ingredient, together with a pharmaceutically acceptable carrier.

4. A pharmaceutical composition for treating hyperproliferative diseases, comprising administering to a subject a compound of claim 1, and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios.

5. The pharmaceutical composition of Claim 4, wherein the disease is selected from cancer, inflammation, pancreatitis, kidney disease, pain, benign hyperplasia of the skin, restenosis, prostate, diseases related to vasculogenesis, diseases related to angiogenesis, tumor angiogenesis, skin diseases, psoriasis, eczema, sclerodema, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma and Kaposi's sarcoma.

6. A kit consisting of separate packs of an effective amount of a compound of claim 1 and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, and an effective amount of a further medicament active ingredient.